About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

HDM1005

Company: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: 5 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

5 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 19, 2026

Trial details

Recruiting NCT NCT06886126

Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus

Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 240 participants Est. completion 2025-11-30 1 site Stand-alone

Other conditions: Obesity
View official trial listing →
Recruiting NCT NCT07109700

A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin

Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 216 participants Est. completion 2026-02-28 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Recruiting NCT NCT07279194

Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes

Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 825 participants Est. completion 2026-12-13 1 site Stand-alone

Other conditions: Obesity & Overweight
View official trial listing →
Recruiting NCT NCT07394114

A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 240 participants Est. completion 2027-12-17 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Recruiting NCT NCT07521631

Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes

Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 372 participants Est. completion 2027-07-23 1 site Stand-alone

Other conditions: Obesity
View official trial listing →
Completed NCT NCT06637020

Phase Ib Clinical Study of HDM1005 Injection

Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 80 participants Est. completion 2025-06-24 1 site Stand-alone

Other conditions: Overweight and Obesity
View official trial listing →
Completed NCT NCT06640647

Phase Ia Clinical Study of HDM1005 Injection

Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 65 participants Est. completion 2024-09-26 1 site Stand-alone

Other conditions: Obesity and Overweight
View official trial listing →
Not yet recruiting NCT NCT07417306

A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 912 participants Est. completion 2027-12-31 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Not yet recruiting NCT NCT07502001

Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin

Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 42 participants Est. completion 2027-06-02 1 site Stand-alone

Other conditions: Overweight, Obesity
View official trial listing →
Not yet recruiting NCT NCT07559240

A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants

Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 30 participants Est. completion 2026-07-31 1 site Stand-alone

Other conditions: Overweight, Obese
View official trial listing →
Not yet recruiting NCT NCT07787260

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy

Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 200 participants Est. completion 2028-06 1 site Stand-alone

Obstructive sleep apnea
View official trial listing →
Not yet recruiting NCT NCT07794397

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) Therapy

Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 200 participants Est. completion 2028-11 1 site Stand-alone

Obstructive sleep apnea
View official trial listing →
Active, not recruiting NCT NCT07828197

A Pharmacokinetic Study of HDM1005 Injection at Different Injection Sites

Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 135 participants Est. completion 2026-11 1 site Stand-alone

Other conditions: Overweight and/or Obesity, Healthy Participants
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT07828197

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.